Tango Therapeutics develops precision oncology drugs built around synthetic lethality—pairing a tumor’s genetic weakness with a targeted therapy so cancer cells die while healthy cells are spared. Its pipeline centers on genetically defined cancers, including programs against PRMT5 and other DNA-damage and gene-regulation targets. The company works mainly in discovery and clinical development rather than marketed products, aiming at patients whose tumors carry specific mutations identified by molecular testing.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 5.4 | — | -39.9 | — |
| Q2 2025 | 3.2 | — | -38.9 | — |
| Q3 2025 | 53.8 | — | 15.9 | — |
| Q4 2025 | 0 | — | -38.8 | — |
| Q1 2026 | 0 | -100% | -45.5 | — |
| Q2 2026 | 0 | -100% | -55.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Interparfums, Inc. (IPAR), ACM Research, Inc. (ACMR), Dorman Products, Inc. (DORM), Palomar Holdings, Inc. (PLMR), BancFirst Corporation (BANF), Itron, Inc. (ITRI)